Biogen Inc

BIIB

Equity

ISIN null / Valor 1720684

NASDAQ (2026-02-25)

USD 190.73-2.25%

Biogen Inc
UMushroom community rating:

4.40 5 votes No rating yet

NegativeNeutralPositive

About company

Biogen Inc is a prominent biotechnology company that focuses on developing therapies for a range of complex and debilitating diseases. Established in 1978, the company has made significant advancements in the field, particularly in neurology, neuropsychiatry, specialized immunology, and rare diseases. Biogen is known for its innovative treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. The company is dedicated to serving humanity through scientific research and is committed to creating a healthier, more sustainable, and equitable world.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

32.9%1Y

-29.4%3Y

-31.2%5Y

Performance

32.9%1Y

27.3%3Y

35.5%5Y

Volatility

27991 M

Market cap (USD)

942,723

Daily traded volume (Shares)

151.14 / 148.23

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.40

5 votes

Performance:

4.20

Innovation:

4.80

Society:

4.20

Nature:

4.00

Tonia Zimmermann

Switzerland, 13 Jun 2023

Not just leading in supporting Alzheimer patience, but also pioneering in digital health.

Igor Jovicic

Switzerland, 13 Jun 2023

A company that seems to be making an impact in the biotech sector!

Luba Schoenig

Switzerland, 13 Jun 2023

FDA Advisory Committee recommended the Food and Drug Administration to approve Leqembi, an Alzheimer's drug from Biogen and its Japanese partner Eisai.

EQUITIES OF THE SAME SECTOR

Schrodinger Inc